CN111011864A

CN111011864A - Nutritional component for promoting intestinal health

Info

Publication number: CN111011864A
Application number: CN201911377872.9A
Authority: CN
Inventors: 逄金柱; 李菊芳; 俞伟祖
Original assignee: Inner Mongolia Mengniu Dairy Group Co Ltd
Current assignee: Inner Mongolia Mengniu Dairy Group Co Ltd
Priority date: 2019-12-27
Filing date: 2019-12-27
Publication date: 2020-04-17
Also published as: AU2020294253B2; AU2020294253A1; NZ771554A

Abstract

The present invention relates to a nutritional composition for promoting gut health, in particular, the nutritional composition contains human milk oligosaccharides and prebiotics, in particular 2 '-fucosyllactose (2' -FL) and a specific ratio of galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS). The nutritional components can be added into food and health products for promoting intestinal maturation, enhancing intestinal immunity, regulating intestinal flora, etc.

Description

Nutritional component for promoting intestinal health

Technical Field

The invention belongs to the field of food biotechnology. More particularly, the present invention relates to a nutritional composition for promoting intestinal health, and food or health food comprising the same and a preparation method thereof. More specifically, the nutritional component contains Human Milk Oligosaccharides (HMO), Galactooligosaccharides (GOS), and Fructooligosaccharides (FOS), wherein the weight ratio of GOS to FOS is about 9: 1.

Background

Studies have shown that the gut flora plays important roles throughout the life of humans, such as barrier function, metabolic response, nutritional effects, and maturation of host innate and adaptive immune responses. Thus, the health of the intestine determines the health of a person throughout life.

Early colonization of infant intestinal flora affects the incidence of metabolic disease after adulthood. Research shows that the intestinal flora composition of infants fed with the formula milk powder and infants fed with breast milk has obvious difference, especially the colonization of bifidobacterium and lactobacillus. The addition of prebiotics (such as breast milk oligosaccharides) beneficial to the colonization of infant intestinal flora in formula milk is the hot spot of current research.

The old age is a further inflection period in which significant changes in the adult intestinal flora occur. The physiological state of the elderly is in the decline phase: gastrointestinal motility dysfunction, gastric acid secretion reduction, degenerative change of the intestinal nervous system, and increment-related intestinal diseases (slow transit constipation of the milk intestinal tract, atrophic gastritis, etc.) can affect the composition and function of intestinal flora. Researches show that dietary supplement of prebiotics can promote proliferation of probiotics, increase the content of SCFAs (soluble fatty acids) to enable volume of excrement to expand, improve vitality degradation of saccharification flora, reduce putrescence-causing fermentation effect, reduce pH value of intestinal tract and improve compatibilization effect, and finally can improve the intestinal tract environment of the old, promote gastrointestinal motility, increase defecation frequency and prevent constipation. Prebiotics are ingredients that confer health to the host by selective fermentation resulting in specific changes in the composition and/or activity of the intestinal microflora. The prebiotics are not destroyed by gastric acid of human body, and are not decomposed by digestive enzyme, and can directly reach large intestine, stimulate the growth of beneficial flora in intestinal tract, indirectly inhibit the growth of harmful flora, and maintain intestinal microecological balance. Fructooligosaccharides (FOS) and Galactooligosaccharides (GOS) are the earliest prebiotics used and have various effects of improving intestinal microbial status, promoting intestinal metabolic movement, enhancing immunity, improving fat metabolism, controlling weight, promoting cardiovascular health, etc.

The metabolism function changes during gestation period, and the composition and abundance of intestinal flora also change. The intestinal flora is closely related to the occurrence of gestational diseases, such as overweight/obesity, hypertension/hyperlipidemia, diabetes, etc. Thus, targeted intervention in the gut flora of pregnant women (e.g., increasing the abundance of gut probiotics) may be beneficial in improving poor pregnancy outcome.

The Human Milk Oligosaccharide (HMO) is the third largest solid component in human breast milk, only after lactose and fat, the HMO is composed of 3-14 monosaccharides, is a linear or branched structure, generally takes lactoyl-N-tetraose (LNT), lactoyl-N-neotetraose (LNnT), lactoyl-N-hexaose (LNH) and lactoyl-N-neohexaose (LNnH) as core structures, can extend or carry out fucosylation and sialylation again to form various HMOs (such as 2 '-FL, 3' -FL, LNT, LNFP I and the like), the HMO which is identified at present has more than 200 kinds, including acidic and neutral oligosaccharides, which are important for intestinal immune system maturation, intestinal function and microorganism, the HMO can directly promote the proliferation of probiotics such as bifidobacterium and the like as a bifidum factor, regulate the intestinal immune pathway, promote the maturation of the intestinal immune system, improve the sensitivity of skeletal bacteria, thereby regulating the quantity of intestinal flora, the intestinal tract bacterial flora, the intestinal tract function and the intestinal tract function, and the metabolism of intestinal tract, the intestinal.

Based on the combination of the human milk oligosaccharide HMO, the classical oligosaccharide combination and the OPO, the invention has the effects on human intestinal health, simultaneously exerts the effects on the three aspects of promoting intestinal maturation, enhancing intestinal immunity and regulating intestinal flora, and provides the synergistic effect of the preferable nutrient components on the intestinal health.

Disclosure of Invention

It is an object of the present invention to provide a nutritional composition for contributing to intestinal health, which contains 2 '-fucosyllactose (2' -FL) for contributing to intestinal maturation and development of the intestinal immune system, galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS) for contributing to regulation of the intestinal flora, and optionally 1, 3-dioleate-2-palmitoyl-triglyceride (OPO) for contributing to softening of feces, promotion of calcium absorption and regulation of the efficacy of the intestinal flora.

Accordingly, in one aspect, the present invention provides a nutritional composition comprising Human Milk Oligosaccharides (HMOs), Galactooligosaccharides (GOS) and Fructooligosaccharides (FOS), wherein the weight ratio of GOS to FOS is about 9: 1.

In a specific embodiment of this aspect, the present invention provides the above nutritional component wherein the weight ratio of HMOs to GOS and FOS in a ratio of about 9:1 is from about 1:1 to about 1:200, preferably from about 1:2 to about 1:100, more preferably from about 1:2 to about 1:30, especially preferably about 1:5, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1:60 or 1: 90.

In another specific embodiment of this aspect, the present invention provides the above nutritional composition, which comprises OPO structural fat blend oil; preferably, the weight ratio of HMO to OPO is from about 1:1 to about 1:200, preferably from about 1:2 to about 1:200, more preferably from about 1:2 to about 1:80, especially preferably about 1:10, 1:20, 1:40, 1:60 or 1: 80.

In another specific embodiment of this aspect, the present invention provides the above nutritional composition, wherein the HMO is selected from the group consisting of fucosyl-enriched human milk oligosaccharides such as 2 '-FL, 3-FL, LNFPI, LNFP II, LNFP III, LNFP V, LNFP VI, LNDFH I, LNDFH II, F-LNH I, F-LNH II, DF-LNH I, DF-LNH II, DF-LNnH, DF-para-LNH, DF-para-LNnH, TF-LNH, and the like, preferably 2' -FL.

In another embodiment of this aspect, the present invention provides the above nutritional component, wherein the nutritional component comprises 2' -FL, GOS, FOS and OPO in a weight ratio of about (0.5-10): 35-40): 3.5-4.5): 40, preferably (1-10): 35-40): 3.5-4.5): 40.

It is another object of the present invention to provide a food or health product for promoting intestinal health, which contains the above-mentioned nutritional ingredients.

In another specific embodiment of this aspect, the present invention provides the above food or health care product, wherein the food or health care product is a milk and dairy product, a fermented flavor food, a beverage, chocolate, candy, baked food, a juice food; preferably, the food or health product is meat, fish, poultry and wild, gravy, pickled, frozen, dried and cooked fruits and vegetables, jelly, jam, preserves, eggs, milk and dairy products, edible oils and fats.

In another specific embodiment of this aspect, the present invention provides the above food or health care product, wherein the food or health care product is infant, maternal and elderly formula, raw or processed cheese, milk drink, solid dairy product, solid drink, ice cream.

The invention also aims to provide the application of the nutrient components in preparing foods or health-care products, wherein the foods or health-care products are milk and dairy products, fermented flavor foods, beverages, chocolates, candies, baked foods and fruit and vegetable juice foods; preferably, the food or health product is meat, fish, poultry and wild, gravy, pickled, frozen, dried and cooked fruits and vegetables, jelly, jam, preserves, eggs, milk and dairy products, edible oils and fats.

In another specific embodiment of this aspect, the present invention provides the above use, wherein the food or health product is infant, maternal and elderly formula, raw or processed cheese, milk drink, solid dairy product, solid drink, ice cream.

Another object of the present invention is to provide a method for preparing an infant formula containing the above nutritional components, comprising the steps of:

(1) adding the water-soluble ingredients into purified water at about 40-65 deg.C to obtain water-soluble raw ingredients;

preferably, the water-soluble ingredient is desalted whey powder, skim milk powder, lactose, galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), 2 '-fucosyllactose (2' -FL);

(2) premixing the oil and fat, and heating to about 40-65 deg.C to obtain fat-soluble raw material;

preferably, the grease is OPO structure grease mixed oil and mixed vegetable oil;

(3) mixing the water-soluble and fat-soluble raw materials, homogenizing, and cooling to about 0-6 deg.C;

preferably, the homogenization pressure is about 100-200 bar;

(4) adding compound vitamins and compound minerals, stirring, sterilizing, concentrating, spray drying, and fluidized bed drying;

preferably, the sterilization temperature is about 75-95 ℃ and the sterilization time is about 20-90 s; the concentration temperature is about 70-90 ℃; the air inlet temperature of the spray drying is about 180-215 ℃, and the air outlet temperature is about 70-90 ℃; the temperature of the fluidized bed drying I, II and III sections is about 15-95 ℃, and the temperature of the IV section is about 15-40 ℃;

(5) and (3) feeding the dried base powder into a dry mixing tank through a powder conveying system, and dry mixing the base powder with functional ingredients needing dry mixing to obtain the infant formula milk powder.

The invention also aims to provide a preparation method of the middle-aged and elderly people formula food containing the nutritional components, which comprises the following steps:

preferably, the water-soluble ingredient is whole milk powder, skim milk powder, lactose, maltodextrin, 2 '-fucosyllactose (2' -FL), fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS);

(2) heating oil to about 40-65 deg.C to obtain liposoluble raw materials;

preferably, the grease is OPO structure grease mixed oil;

preferably, the homogenization pressure is about 100-200 bar;

(4) adding compound vitamins, compound minerals and other food additives, stirring, sterilizing, concentrating, spray drying, and fluidized bed drying;

preferably, the other food additive is citric acid; preferably, the sterilization temperature is about 75-95 ℃ and the sterilization time is about 20-90 s; the concentration temperature is about 70-90 ℃; the air inlet temperature of the spray drying is about 180-215 ℃, and the air outlet temperature is about 70-90 ℃; the temperature of the fluidized bed drying I, II and III sections is about 15-95 ℃, and the temperature of the IV section is about 15-40 ℃;

(5) and (3) feeding the dried base powder into a dry mixing tank through a powder conveying system, and dry mixing the base powder with functional ingredients needing dry mixing to obtain the formula milk powder for the middle-aged and the elderly.

Another object of the present invention is to provide a method for preparing a maternal formula food containing the above nutritional ingredients, comprising the steps of:

preferably, the water-soluble ingredient is whole milk powder, skim milk powder, concentrated whey protein powder, lactose, galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), 2 '-fucosyllactose (2' -FL);

(2) heating oil to about 40-65 deg.C to obtain liposoluble raw materials;

preferably, the grease is OPO structure grease mixed oil;

preferably, the homogenization pressure is about 100-200 bar;

(5) and (3) feeding the dried base powder into a dry mixing tank through a powder conveying system, and dry mixing the dried base powder with functional ingredients needing dry mixing to obtain the pregnant and lying-in woman formula milk powder.

Drawings

In order to more clearly illustrate the technical solution of the present invention, the present invention will be described in detail with reference to the accompanying drawings. It is to be expressly understood that the drawings are only illustrative of some specific embodiments of the invention and are not intended as a definition of the limits of the invention.

FIG. 1 is a graph of the effect of different nutritional component interventions on the relative abundance of bifidobacteria in the intestinal tract of rats;

FIG. 2 is a graph of the relative content of sIgA in the intestinal content after dry prognosis for different nutritional components;

FIG. 3 shows the relative abundance of bifidobacteria in intestinal tracts of newborn mice fed with different infant formulas;

FIG. 4 shows the relative content of sIgA in intestinal contents after intervention of different infant formulas;

FIG. 5 shows the growth ratio of the relative abundance of bifidobacteria after treating feces of the elderly with different middle-aged and elderly people formula milk powders;

FIG. 6 shows the growth ratio of the relative abundance of bifidobacteria in the feces of pregnant women in the middle of pregnancy treated by different pregnant and lying-in women formula milk powders.

Detailed description of the preferred embodiments

Definition of

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs, but in the event of conflict, the definitions set forth herein shall control.

As used in the specification and in the claims, the singular form of "a", "an", and "the" include plural referents unless the context clearly dictates otherwise.

Unless otherwise specified, the percentages (%) in this specification are all weight percentages (% by weight).

All numbers or expressions referring to quantities of ingredients, process conditions, etc. used in the specification and claims are to be understood as modified in all instances by the term "about". The term "about" when referring to a quantity or range of values means that the quantity or range of values referred to is within experimental variability (or statistical)Within the error of a chemical experiment), and thus the quantity or numerical range may be within the quantity or numerical range, for example+5, or a combination thereof.

All ranges directed to the same component or property are inclusive of the endpoints, and independently combinable. Because these ranges are continuous, they include every value between the minimum and maximum values. It should also be understood that any numerical range recited herein is intended to include all sub-ranges within that range.

When the present invention is directed to a physical property, such as molecular weight, or to a range of chemical properties, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term "comprising" (and related terms such as "comprising" or "including" or "having" or "including") includes embodiments that are, for example, any combination of materials, compositions, methods, or processes that "consist of or" consist essentially of the recited features.

As used in this specification and claims, "and/or" should be understood to mean "either or both" of the associated components, i.e., the components may be present in combination in some instances and separately in other instances. A plurality of components listed with "and/or" should be understood in the same way, i.e., "one or more" of the associated component. In addition to the "and/or" clause-specific components, other components may optionally be present, whether related or unrelated to those specifically identified components. Thus, as a non-limiting example, reference to "a and/or B," when used in conjunction with open ended words such as "comprising," may refer in one embodiment to a alone (optionally including components other than B); in another embodiment, reference may be made to B alone (optionally including components other than a); in yet another embodiment, refers to a and B (optionally including other components), and the like.

As used in this specification and the claims, the term "or" should be understood to have the same meaning as "and/or" as defined above. For example, when items are separated in a list, "or" and/or "should be interpreted as being inclusive, i.e., including at least one of more or components of the list, but also including more than one, and optionally other unlisted items. Only terms specifically directed to an opposite face such as "only one" or "exactly one," or "consisting of …" as used in the claims, shall mean including exactly one of the plurality or list of components. In general, the term "or" as used herein is considered to refer to an exclusive choice (i.e., one or the other but not both) only when there is an exclusive antecedent such as "or" one, "" only one, "or" exactly one.

It is to be understood that, unless explicitly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.

The abbreviations used in the present invention have the usual meaning in the food, biological and chemical fields.

Nutritional components

The nutritional components of the present invention have (but are not limited to) the following functions:

regulating intestinal flora, proliferating beneficial bacteria, and inhibiting harmful bacteria; can be used as an anti-adhesion antibacterial agent, and can prevent pathogens from adhering to intestinal mucosa surface in a soluble bait receptor manner, thereby reducing infection risk; regulating epidermal cell and immune cell responses, and reducing transitional infiltration and transitional activation of mucosal leukocytes; reducing the risk of the occurrence of necrotizing enterocolitis, etc., and in particular may exert unique functional properties in different populations:

1) promoting the intestinal health of infants: the difference of the oligosaccharide composition is the main difference nutrient in cow milk and breast milk, the infant formula milk powder is developed on the basis of cow milk, the oligosaccharide close to the breast milk is supplemented, so that the difference between the infant formula milk powder and the breast milk can be reduced, and the intestinal development and the health level of infants fed by the formula milk powder are promoted to be closer to those of infants fed by the breast milk.

2) Promote the intestinal health of the middle-aged and the elderly: the intestinal flora imbalance and the intestinal function decline are main problems of the intestinal health of the middle-aged and the elderly, and the nutritional component can play the roles of adjusting the intestinal flora, enhancing the intestinal immunity, helping the intestinal peristalsis and the like, and solve the intestinal health problem of the middle-aged and the elderly.

3) The intestinal health of pregnant and lying-in women is promoted: the intestinal health of pregnant women is related to various diseases such as diabetes, hypertension and the like in the pregnant women, the healthy intestinal microecology is the key of healthy pregnancy, the nutritional components are beneficial to regulating intestinal flora of pregnant and lying-in women, preventing and treating diarrhea and constipation, and the intestinal health problem of the pregnant and lying-in women can be solved.

The present invention relates to a nutritional composition for contributing to gut health comprising 2 '-fucosyllactose (2' -FL) for contributing to gut maturation and development of the gut immune system, Galactooligosaccharides (GOS) and Fructooligosaccharides (FOS) for contributing to the regulation of the gut flora and optionally 1, 3-dioleoyl-2-palmitoyl-triglyceride (OPO) for contributing to softening of the stool, promotion of calcium absorption and regulation of the gut flora efficacy.

It is particularly important that the combination of the above components in a specific ratio provides an unexpected synergistic effect with respect to the individual effects of each component or the additive effects thereof. The specific proportions are as detailed below:

wherein, the content of 2 '-fucose lactose (2' -FL) is 0.1-10 parts (preferably 1-10 parts), the content of galacto-oligosaccharide (GOS) and fructo-oligosaccharide (FOS) (GOS: FOS ═ 1:1-15:1) is 10-50 parts, and the content of 1, 3-dioleic acid-2-palmitic acid-triglyceride (OPO) structure fat mixed oil is 80-120 parts (wherein, the OPO is 32-48 parts).

Preferably, the 2 '-fucosyllactose (2' -FL) is 1 to 10 parts, more preferably 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts or any range therebetween, and particularly preferably 1 to 2 parts, and particularly preferably 1.5 parts.

Preferably, the ratio of galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS) is GOS: FOS ═ 2:1, GOS: FOS ═ 3:1, GOS: FOS ═ 4:1, GOS: FOS ═ 5:1, GOS: FOS ═ 6:1, GOS: FOS ═ 7:1, GOS: FOS ═ 8:1, GOS: FOS ═ 9:1, GOS: FOS ═ 10:1, GOS: FOS ═ 11:1, GOS: FOS ═ 12:1, GOS: FOS ═ 13:1, GOS: FOS ═ 14:1 or any range therebetween, particularly preferably GOS: FOS ═ 8:1 to 10:1, particularly preferably GOS: FOS ═ 9: 1.

Preferably, the amount of galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS) is 15 parts, 20 parts, 25 parts, 30 parts, 35 parts, 40 parts, 45 parts or any range therebetween, especially preferably 35 to 45 parts, and particularly preferably 40 parts.

Preferably, the amount of the OPO structural fat-mixed oil is 50 parts, 60 parts, 70 parts, 80 parts, 90 parts, 100 parts, 110 parts or any range therebetween, and particularly the amount of the OPO structural fat-mixed oil is preferably 90 to 110 parts, and particularly the amount of the OPO structural fat-mixed oil is preferably 100 parts, wherein the OPO structural fat-mixed oil contains 20 parts, 24 parts, 28 parts, 32 parts, 36 parts, 40 parts, and 44 parts of OPO, preferably 36 parts to 44 parts, and particularly preferably 40 parts of OPO.

Food or health product

The nutritional component of the invention can be added to any food or health care product to prepare the food or health care product with the specific function of the nutritional component of the invention (for example, for promoting the intestinal health of infants, middle-aged and elderly people and pregnant and lying-in women).

For example, the food or health care product to which the nutritional component of the present invention may be added is milk and dairy products, fermented flavor foods, beverages, chocolate, candies, baked goods, fruit and vegetable juice foods; preferably, the food or health product is meat, fish, poultry and wild, gravy, pickled, frozen, dried and cooked fruits and vegetables, jelly, jam, preserves, eggs, milk and dairy products, edible oils and fats.

More specifically, the food or health care product is infant, pregnant and lying-in women, middle-aged and elderly people formula food, raw cheese or processed cheese, milk beverage, solid dairy product, solid beverage and ice cream.

Specific product and preparation method thereof

The nutritional composition of the invention may be used for the preparation of a food or health product as specifically mentioned above, in particular a formula for infants, pregnant women, elderly people.

In a particular embodiment, the food or health product is an infant formula comprising the following main ingredients:

2 ' -Fucosyllactose (2 ' -fucosylactose, 2 ' -FL), galacto-oligosaccharide (GOS), fructo-oligosaccharide (FOS), OPO structure fat mixed oil, skimmed milk powder, mixed vegetable oil, desalted whey powder, lactose, compound mineral matter, and compound vitamin.

The OPO structure fat mixed oil is a mixed oil taking 1, 3-dioleic acid-2-palmitic acid triglyceride as a main component and is composed of sunflower seed oil, coconut oil, soybean oil and linseed oil.

The mixed vegetable oil comprises sunflower seed oil, coconut oil, corn oil, low erucic acid rapeseed oil and soybean oil.

The compound mineral comprises calcium carbonate, magnesium sulfate, sodium citrate, potassium chloride, ferrous sulfate, zinc sulfate, copper sulfate and manganese sulfate.

The compound vitamin comprises vitamin A acetate powder, vitamin D3 powder, L-ascorbic acid, L-sodium ascorbate, dl- α -tocopherol acetate powder, thiamine nicotinate, riboflavin, pyridoxine hydrochloride, cyanocobalamine, phytomenadione, folic acid, nicotinamide, D-calcium pantothenate, inositol and taurine.

Preferably, the weight parts of the components are as follows: 0.1-10 parts of 2 '-fucose lactose (2' -FL), 2-20 parts of galacto-oligosaccharide (GOS) and 0.2-2 parts of fructo-oligosaccharide (FOS); 8-20 parts of OPO structure fat mixed oil (containing 3.2-8 parts of OPO) and 10-20 parts of mixed vegetable oil; 10-25 parts of skim milk powder and 35-60 parts of desalted whey powder; 2-12 parts of lactose; 0.2-2 parts of compound mineral; 0.05-0.5 part of compound vitamin.

The feed also comprises the following auxiliary material components in parts by weight: 0.002-0.2 part of lutein, 0.001-0.1 part of taurine, 0.005-0.05 part of L-carnitine tartrate, 0.01-0.3 part of choline chloride and 0.001-0.1 part of nucleotide.

In the OPO structure fat mixed oil, the weight percentages of the sunflower seed oil, the coconut oil, the soybean oil and the linseed oil are respectively 30-50%, 25-50%, 10-20% and 1-10%, wherein the weight percentage of the contained OPO is 10-40%.

In the refined vegetable oil, the weight percentages of the sunflower seed oil, the coconut oil, the corn oil, the low erucic acid rapeseed oil and the soybean oil are respectively 20-50%, 10-30%, 10-20% and 5-15%.

The nucleotide comprises 5 ' adenosine monophosphate, 5 ' -creatinine disodium, 5 ' -ornithine disodium, 5 ' -uric acid disodium and 5 ' -cytidine disodium.

The compound mineral comprises the following components in percentage by weight: 10 to 40 percent of calcium carbonate, 10 to 20 percent of magnesium sulfate, 10 to 30 percent of sodium citrate, 15 to 40 percent of potassium chloride, 1 to 5 percent of ferrous sulfate, 0.3 to 3 percent of zinc sulfate, 0.02 to 0.2 percent of copper sulfate and 0.005 to 0.05 percent of manganese sulfate.

The compound vitamin comprises, by weight, 1.2-3.6% of vitamin A acetate powder, 0.5-2% of vitamin D3 powder, 10-30% of L-ascorbic acid, 10-20% of sodium L-ascorbate, 2-8% of dl- α -tocopheryl acetate powder, 0.1-0.5% of thiamine nicotinate, 1-3% of riboflavin, 0.05-0.15% of pyridoxine hydrochloride, 0.01-0.5% of cyanocobalamine, 0.1-0.8% of menadione, 0.2-0.6% of folic acid, 0.5-1.5% of nicotinamide, 0.2-2% of calcium D-pantothenate, 10-30% of inositol and 10-30% of taurine.

The nucleotide comprises the following components in percentage by weight: 10 to 30 percent of 5 ' adenosine monophosphate, 25 to 45 percent of 5 ' -disodium creatinine, 2 to 13 percent of 5 ' -disodium ornithine, 10 to 34 percent of 5 ' -disodium urate and 5 to 20 percent of 5 ' -disodium cytidylate.

In another embodiment, the method for preparing the infant formula comprises the following steps:

(1) adding the water-soluble ingredients into purified water at about 40-65 deg.C to obtain water-soluble raw ingredients; preferably, the water-soluble ingredient is desalted whey powder, skim milk powder, lactose, galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), 2 '-fucosyllactose (2' -FL);

(2) premixing the oil and fat, and heating to about 40-65 deg.C to obtain fat-soluble raw material; preferably, the grease is OPO structure grease mixed oil and mixed vegetable oil;

(3) mixing the water-soluble and fat-soluble raw materials, homogenizing, and cooling to about 0-6 deg.C; preferably, the homogenization pressure is about 100-200 bar;

(4) adding compound vitamins and compound minerals, stirring, sterilizing, concentrating, spray drying, and fluidized bed drying; preferably, the sterilization temperature is about 75-95 ℃ and the sterilization time is about 20-90 s; the concentration temperature is about 70-90 ℃; the air inlet temperature of the spray drying is about 180-215 ℃, and the air outlet temperature is about 70-90 ℃; the temperature of the fluidized bed drying I, II and III sections is about 15-95 ℃, and the temperature of the IV section is about 15-40 ℃;

In another embodiment, the food or health product is a formula for middle aged and elderly people, which comprises the following main components: 2' -FL, galacto-oligosaccharide (GOS), fructo-oligosaccharide (FOS), OPO structure fat mixed oil, whole milk powder, skimmed milk powder, refined soybean oil, lactose, soybean phospholipid, maltodextrin, compound vitamins, ferrous sulfate, calcium carbonate, zinc sulfate, citric acid and potassium hydroxide.

The OPO structure fat mixed oil is mixed oil taking 1, 3-dioleic acid-2-palmitic acid triglyceride as a main component and is composed of sunflower seed oil, coconut oil, soybean oil and linseed oil.

The compound vitamins comprise vitamin A acetate powder, vitamin D3 powder, L-ascorbic acid, sodium L-ascorbate and dl- α -tocopherol acetate powder.

Preferably, the content ratio of the components is 0.001-1 part of 2' -FL, 0.05-5 parts of galacto-oligosaccharide (GOS), 0.001-0.1 part of fructo-oligosaccharide (FOS), 0.5-5 parts of OPO structure fat mixed oil (containing 0.2-2 parts of OPO), 20-60 parts of whole milk powder, 20-50 parts of skim milk powder, 0-1 part of refined soybean oil, 5-20 parts of lactose, 0.01-2 parts of soybean phospholipid, 5-20 parts of maltodextrin, 0.01-1 part of compound vitamin, 0.01-0.1 part of ferrous sulfate, 0.5-2 parts of calcium carbonate, 0.01-1 part of zinc sulfate, 0.01-1 part of citric acid and 0.01-1 part of potassium hydroxide.

The compound vitamin comprises the following components, by weight, 0.1% -1% of vitamin A acetate powder, 0.001% -0.1% of vitamin D3 powder, 40% -80% of L-ascorbic acid, 10% -30% of L-sodium ascorbate and 5% -20% of dl- α -tocopherol acetate powder.

In another embodiment, the preparation method of the formula milk powder for middle aged and elderly people comprises the following steps:

(1) adding the water-soluble ingredients into purified water at about 40-65 deg.C to obtain water-soluble raw ingredients; preferably, the water-soluble ingredient is skim milk powder, whole milk powder, lactose, maltodextrin, 2 '-fucosyllactose (2' -FL), fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS);

(2) heating oil to about 40-65 deg.C to obtain liposoluble raw materials; preferably, the oil is edible vegetable oil;

(4) adding compound vitamins, compound minerals and other food additives, stirring, sterilizing, concentrating, spray drying, and fluidized bed drying; preferably, the other food additive is citric acid; preferably, the sterilization temperature is about 75-95 ℃ and the sterilization time is about 20-90 s; the concentration temperature is about 70-90 ℃; the air inlet temperature of the spray drying is about 180-215 ℃, and the air outlet temperature is about 70-90 ℃; the temperature of the fluidized bed drying I, II and III sections is about 15-95 ℃, and the temperature of the IV section is about 15-40 ℃;

In another embodiment, the food or health product is a maternal formula comprising the following major ingredients: 2' -FL, galacto-oligosaccharide (GOS), fructo-oligosaccharide (FOS), OPO structure fat mixed oil, whole milk, skimmed milk powder, concentrated whey protein powder, lactose, maltodextrin, white granulated sugar, refined soybean oil, soybean lecithin, choline chloride, docosahexaenoic acid, compound vitamins, ferrous sulfate, zinc sulfate, copper sulfate, citric acid monohydrate and potassium hydroxide.

Wherein the OPO structure fat mixed oil is a mixed oil with 1, 3-dioleoyl-2-palmitic acid triglyceride as a main component, and is composed of sunflower seed oil, coconut oil, soybean oil and linseed oil.

The compound vitamin comprises vitamin A acetate powder, vitamin D3 powder, cyanocobalamine and folic acid.

Preferably, the content ratio of the components is 0.001-0.1 part of 2' -FL, 0.01-1 part of galacto-oligosaccharide (GOS), 0.001-0.1 part of fructo-oligosaccharide (FOS), 0.5-5 parts of OPO structure fat mixed oil (containing 0.2-2 parts of OPO), 20-45 parts of whole milk, 15-35 parts of skim milk powder, 2-10 parts of concentrated whey protein powder, 2-10 parts of lactose, 10-30 parts of maltodextrin and 1-3 parts of white granulated sugar, 0-1 part of refined soybean oil, 0.1-1 part of soybean lecithin, 0.05-0.5 part of choline chloride, 0.2-2 parts of docosahexaenoic acid, 0.01-0.3 part of compound vitamin, 0.01-0.1 part of ferrous sulfate, 0.02-0.2 part of zinc sulfate, 0.001-0.1 part of copper sulfate, 0.01-0.1 part of citric acid monohydrate and 0.05-0.5 part of potassium hydroxide.

The compound vitamin comprises the following components in percentage by weight: 20 to 35 percent of vitamin A acetate powder, 0.02 to 2 percent of vitamin D3 powder, 0.01 to 1 percent of cyanocobalamin and 40 to 65 percent of folic acid.

In another embodiment, the preparation method of the maternal formula comprises the following steps:

(1) adding the water-soluble ingredients into purified water at about 40-65 deg.C to obtain water-soluble raw ingredients; preferably, the water-soluble ingredient is skim milk powder, whole milk powder, concentrated whey protein powder, lactose, 2 '-fucosyllactose (2' -FL), fructo-oligosaccharide (FOS), galacto-oligosaccharide (GOS);

DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION

Nutritional Components example A

Example a 1: nutrient component 1

Comprises 0.15 part of 2 '-fucose lactose (2' -FL), 3.87 parts of galacto-oligosaccharide (GOS) and 0.43 part of fructo-oligosaccharide (FOS). Wherein the ratio of GOS to FOS is 9:1, and the ratio of 2' -FL to (GOS + FOS) is 1.5: 43.

Example a 2: nutrient component 2

Comprises 0.15 part of 2 '-fucose lactose (2' -FL), 3.87 parts of galacto-oligosaccharide (GOS), 0.43 part of fructo-oligosaccharide (FOS) and 10 parts of OPO structure fat mixed oil (containing 4 parts of OPO). Wherein, the ratio of GOS to FOS is 9:1, the ratio of 2 '-FL to (GOS + FOS) is 1.5:43, and the ratio of 2' -FL to (GOS + FOS) to OPO is 1.5:43: 40.

Example a 3: nutrient component 3

Comprises 0.75 part of 2 '-fucose lactose (2' -FL), 3.87 parts of galacto-oligosaccharide (GOS) and 0.43 part of fructo-oligosaccharide (FOS). Wherein the ratio of GOS to FOS is 9:1, and the ratio of 2' -FL to (GOS + FOS) is 7.5: 43.

Example a 4: nutrient component 4

Comprises 0.75 part of 2 '-fucose lactose (2' -FL), 3.87 parts of galacto-oligosaccharide (GOS), 0.43 part of fructo-oligosaccharide (FOS) and 10 parts of OPO structure fat mixed oil (containing 4 parts of OPO). Wherein, the ratio of GOS to FOS is 9:1, the ratio of 2 '-FL to (GOS + FOS) is 7.5:43, and the ratio of 2' -FL to (GOS + FOS) to OPO is 7.5:43: 40.

Example a 5: nutrient component 5

Contains 0.75 part of 2 '-fucose lactose (2' -FL).

Example a 6: nutrient component 6

Comprises 3.87 parts of galacto-oligosaccharide (GOS) and 0.43 part of fructo-oligosaccharide (FOS). Wherein the ratio of GOS to FOS is 9: 1.

Example a 7: nutrient component 7

Comprises 0.05 part of 2 '-fucose lactose (2' -FL), 3.87 parts of galacto-oligosaccharide (GOS) and 0.43 part of fructo-oligosaccharide (FOS). Wherein the ratio of GOS to FOS is 9:1, and the ratio of 2' -FL to (GOS + FOS) is 0.5: 43.

Example A8: nutrient component 8

Comprises 0.05 part of 2 '-fucose lactose (2' -FL), 3.87 parts of galacto-oligosaccharide (GOS), 0.43 part of fructo-oligosaccharide (FOS) and 10 parts of OPO structure fat mixed oil (containing 4 parts of OPO). Wherein, the ratio of GOS to FOS is 9:1, the ratio of 2 '-FL to (GOS + FOS) is 0.5:43, and the ratio of 2' -FL to (GOS + FOS) to OPO is 0.5:43: 40.

The effect testing method comprises the following steps:

in the invention, the experimental method for evaluating the efficacy of the nutritional components on the intestinal health comprises the following steps:

SD rat in vivo experiment is adopted to investigate the regulating effect of the nutrient components on rat intestinal flora colonization, intestinal tissue morphological development and intestinal immunity function.

(1) Grouping of laboratory animals

SD rats 15 were selected and randomly assigned to feeding groups containing different nutritional components, and the addition ratio of 2' -FL, GOS, FOS and OPO in each group is shown in Table 1, for example. After 20 days of continuous feeding, the animals were sacrificed and biological samples were collected for testing.

Table 1 rat groups and ratios of nutritional components (%) -for each feeding

(2) Collecting a biological sample:

intestinal tissues and intestinal contents of suckling mice are collected.

(3) Detecting a biological sample:

detecting the intestinal flora: quantitative analysis of intestinal flora was performed using 16S rDNA.

Detecting intestinal development indexes: villus length and crypt depth; proliferation and differentiation of intestinal epithelial cells the number of Ki-67 nuclear antigen positive cells, enteroendocrine cells, Pan cells and goblet cells were detected by immunofluorescence; intestinal barrier function is quantitatively reflected by the intestinal epithelial cell tight junction protein Claudin-3 membrane localization.

And (3) short-chain fatty acid detection: short chain fatty acids in intestinal contents were detected by gas chromatography.

And (3) detecting the content of sIgA in the intestinal tract: and detecting the sIgA content in the intestinal tract by using an enzyme-linked immunosorbent assay (ELISA).

(4) The experimental results are as follows:

in order to investigate the effects of the nutritional components in the present invention, the rat model was used to investigate the effects of different nutritional components on the composition of intestinal flora, the development of intestinal tissue and the intestinal immunity.

The results of the study showed that the relative abundance of Bifidobacterium bifidum at the genus level in the intestines of rats of the different nutrient feeding groups was significantly different, as shown in fig. 1. It can be seen from fig. 1 that the relative abundance of Bifidobacterium at genus level was significantly higher in the first 4 groups than in the second 4 groups. In the first 4 groups, no significant difference was found between group 1 and group 3(p > 0.05), no significant difference was found between group 2 and group 4 (p > 0.05), but

groups

2 and 4 were significantly higher than groups 1 and 3(p < 0.05) by the analysis of the significance of the differences. This suggests that addition of OPO further enhances bifidobacteria colonization of the gut. While the addition of high doses of 2' -FL does not contribute much to further increase of the relative abundance of bifidobacteria in the intestinal tract. Considering the comprehensive cost value, 2' -FL (GOS + FOS) and OPO have a ratio of 1.5:43:40, and the ratio of GOS to FOS is 9:1, so that the biological agent has a remarkable effect on colonization of beneficial intestinal flora.

The results of the different nutritional components on the development of intestinal tissues show that the different nutritional components have no significant difference (p is more than 0.05) between the jejunal, colon and ileal villus height and crypt depth groups, but have significant difference in epithelial cell proliferation, differentiation and claudin expression, and the results are shown in table 2.

TABLE 2 Effect of different nutritional intervention on intestinal epithelial cell development

Ki-67 is a nuclear antigen associated with proliferating cells and represents the proliferation of the cells. From table 2, it can be seen that the expression quantity of Ki-67 positive cells in group 2, group 3 and group 4 is significantly higher than that in other groups, indicating that the intervention of the three groups of nutritional components is beneficial to the proliferation of intestinal epithelial cells, thereby promoting the development of intestinal tract. The investigation of intestinal epithelial cell differentiation mainly included the effect of different nutritional components on intestinal epithelial endocrine cell, intestinal epithelial goblet cell and intestinal epithelial Pan cell differentiation. The differentiation of these three cells was mainly characterized by the number of 5-HT, MUC2 and lysozyme-positive cells. From table 2, it can be seen that the numbers of lysozyme-positive cells were not significantly different between the 8 groups, indicating that the effect of the intervention of the 8 nutritional components on the differentiation of intestinal epithelial panne cells was not significantly different. While the 5-HT positive cells and MUC2 positive cells were significantly higher in

groups

2 and 4 than in the other groups, indicating that intervention in

groups

2 and 4 had a significant effect on the differentiation of intestinal epithelial endocrine cells and goblet cells. The intestinal barrier function is reflected by the intestinal epithelial cell Claudin-3 membrane localization number, and table 2 shows that the intestinal epithelial cell Claudin-3 membrane localization number after group 2, group 3 and group 4 stem is significantly higher than that of the other groups.

From the viewpoint of the comprehensive proliferation, differentiation and barrier function of the intestinal epithelium, the nutritional intervention of the group 2 has the greatest influence on the development of the intestinal tract, and is most beneficial to the healthy development of the intestinal tract.

The nutritional composition of the present invention includes three prebiotics, 2' -FL, GOS and FOS, which are available to the probiotic bacteria to produce Short Chain Fatty Acids (SCFAs) upon reaching the colon. The generation of SCFAs can reduce the pH value of the intestinal tract, thereby inhibiting the proliferation of harmful bacteria, and the SCFAs can directly act on the epithelial cells of the intestinal tract, which is helpful for maintaining the barrier function of the intestinal mucosa. Therefore, the promotion effect of different nutritional components on the healthy development of the intestinal tract can be further illustrated by comparing the production amount of the SCFAs. Table 3 shows the dry prognosis of several SCFAs content for different nutritional components. From table 3, it can be seen that the total SCFAs were present in the first 4 groups with no significant difference, significantly higher than in the last 4 groups. Whereas the acetic acid, isobutyric acid in group 2, group 3 and group 4 were significantly higher in the first 4 groups than in group 1. Overall, there was no significant difference in the production of SCFAs in the gut following the drying of the different nutritional components of

groups

2, 3 and 4.

TABLE 3 Dry prognosis of SCFAs content in colon (μmol/g) for different nutritional components

Meanwhile, in order to investigate the influence of intervention of different nutritional components on intestinal immunity, the research performs group comparison on the relative content of sIgA in intestinal contents. The results are shown in fig. 2, from which it can be seen that the relative content of sIgA in the intestinal contents after the group 2 nutritional component dry prognosis is significantly higher than that of the other groups (p < 005).

Formula milk powder example B

Example B1: formula milk powder (0-6 months old) for promoting intestinal health of infants

1. Raw materials

F1 formula:

16.3 percent of skim milk powder, 48.49 percent of desalted whey powder, 7.01 percent of lactose, 27.5 percent of mixed vegetable oil and a nutrition enhancer.

Wherein the mixed vegetable oil comprises: the vegetable oil comprises palm oil, sunflower seed oil, rapeseed oil, palm kernel oil, corn oil and coconut oil, wherein the ratio of the palm oil to the sunflower seed oil to the rapeseed oil to the palm kernel oil to the corn oil to the coconut oil is respectively as follows: 35%, 27.5%, 27%, 4%, 3.5% and 3%.

Nutrient supplements including minerals and vitamins; the method specifically comprises the following steps: 0.12% of lutein, 0.032% of choline chloride, 0.042% of inositol, 0.017% of L-carnitine tartrate, 0.047% of nucleotide, 0.062% of taurine, 0.24% of compound mineral, 0.14% of compound vitamin and a dry mixed nutrient mixture;

wherein, the nucleotide comprises 17.56% of cytidine 5 '-monophosphate (5' -CMP); 11.56% of adenosine 5 '-monophosphate (5' -AMP); 10.44 percent of disodium 5 ' -creatinine, 4.67 percent of disodium 5 ' -guanylate and 17.56 percent of disodium 5 ' -uridylate;

the compound minerals comprise 5.8 percent of ferrous sulfate, 4.32 percent of zinc sulfate, 0.96 percent of sodium selenite, 56.9 percent of magnesium sulfate, 0.31 percent of copper sulfate, 0.093 percent of manganese sulfate and 0.77 percent of citric acid;

the compound vitamins comprise 2.2 percent of cholecalciferol, 10.4 percent of dl- α -tocopheryl acetate, 0.82 percent of plant menadione, 0.56 percent of thiamine hydrochloride, 0.11 percent of riboflavin, 0.32 percent of pyridoxine hydrochloride, 0.95 percent of cyanocobalamine, 2.9 percent of nicotinamide, 0.01 percent of D-biotin, 17 percent of inositol, 0.08 percent of folic acid, 1.97 percent of D-calcium pantothenate and 23.5 percent of taurine;

the dry blended nutrient mix includes retinyl acetate, sodium L-ascorbate, and lutein in proportions of 3.65%, 55.55%, and 13.7% of the total dry blended nutrient premix, respectively.

Wherein, the formula does not contain oligosaccharide.

F2 formula:

16.3 percent of skim milk powder, 48.49 percent of desalted whey powder, 6.13 percent of lactose, 27.5 percent of mixed vegetable oil and a nutrition enhancer.

Wherein the mixed vegetable oil comprises palm oil, sunflower seed oil, rapeseed oil, palm kernel oil, corn oil and coconut oil, which respectively account for the following total vegetable oil: 35%, 27.5%, 27%, 4%, 3.5% and 3%.

Nutrient supplements including oligosaccharides, minerals and vitamins; specifically comprises 0.45 percent of galacto-oligosaccharide (GOS), 0.43 percent of fructo-oligosaccharide (FOS), 0.12 percent of lutein, 0.032 percent of choline chloride, 0.042 percent of inositol, 0.017 percent of L-carnitine tartrate, 0.047 percent of nucleotide, 0.062 percent of taurine, 0.24 percent of compound mineral, 0.14 percent of compound vitamin and a dry mixed nutrient mixture;

Wherein the ratio of GOS to FOS is about 1: 1.

F3 formula:

14.5 percent of skim milk powder, 46.72 percent of desalted whey powder, 6.13 percent of lactose, 17.5 percent of mixed vegetable oil, 10 percent of OPO structural fat mixed oil (containing OPO 4 percent) and a nutrition enhancer.

Wherein the mixed vegetable oil comprises palm oil, sunflower seed oil, rapeseed oil, palm kernel oil, corn oil and coconut oil, and the proportions of the mixed vegetable oil in the total vegetable oil are as follows: 35%, 27.5%, 27%, 4%, 3.5% and 3%.

The OPO structure fat mixed oil consists of 42 percent of sunflower seed oil, 36 percent of coconut oil, 16 percent of soybean oil and 6 percent of linseed oil, wherein the proportion of 1, 3-dioleate-2-palmitic acid triglyceride in the mixed oil is 40 percent.

Nutrient supplements including oligosaccharides, minerals and vitamins; the feed additive specifically comprises 0.15% of 2' -FL, 3.87% of galacto-oligosaccharides (GOS), 0.43% of fructo-oligosaccharides (FOS), 0.12% of lutein, 0.032% of choline chloride, 0.042% of inositol, 0.017% of L-carnitine tartrate, 0.047% of nucleotide, 0.062% of taurine, 0.24% of compound mineral, 0.14% of compound vitamin and a dry mixed nutrient mixture;

the compound mineral comprises: 5.8% of ferrous sulfate, 4.32% of zinc sulfate, 0.96% of sodium selenite, 56.9% of magnesium sulfate, 0.31% of copper sulfate, 0.093% of manganese sulfate and 0.77% of citric acid;

the dry blended nutrient mix comprised retinyl acetate, sodium L-ascorbate, and lutein, at ratios of 3.65%, 55.55%, and 13.7% of the total dry blended nutrient premix, respectively.

Wherein the ratio of 2' -FL, (GOS + FOS) and OPO is 1.5:43: 40.

F4 formula:

14.2 percent of skim milk powder, 46.42 percent of desalted whey powder, 6.13 percent of lactose, 17.5 percent of mixed vegetable oil, 10 percent of OPO structural fat mixed oil (containing OPO 4 percent) and a nutrition enhancer;

wherein the mixed vegetable oil comprises palm oil, sunflower seed oil, rapeseed oil, palm kernel oil, corn oil and coconut oil, and the proportions of the mixed vegetable oil in the total vegetable oil are as follows: 35%, 27.5%, 27%, 4%, 3.5% and 3%;

Nutrient supplements including oligosaccharides, minerals and vitamins; the nutrient solution specifically comprises 0.75% of 2' -FL, 3.87% of galacto-oligosaccharides (GOS), 0.43% of fructo-oligosaccharides (FOS), 0.12% of lutein, 0.032% of choline chloride, 0.042% of inositol, 0.017% of L-carnitine tartrate, 0.047% of nucleotide, 0.062% of taurine, 0.24% of compound mineral, 0.14% of compound vitamin and a dry mixed nutrient mixture.

Wherein the ratio of 2' -FL, (GOS + FOS) and OPO is 7.5:43: 40.

2. Preparation method

The preparation method adopts a dry-wet mixing production process and comprises the following steps:

(1) putting desalted whey powder, skimmed milk powder, lactose, 2' -FL, galacto-oligosaccharide (GOS) and fructo-oligosaccharide (FOS) into purified water at 60 ℃ according to a certain proportion to obtain a water-soluble raw ingredient;

(2) pre-mixing the OPO structure fat mixed oil and the mixed vegetable oil according to the proportion, and heating to 60 ℃ to obtain a fat-soluble raw ingredient;

(3) mixing the water-soluble raw ingredients obtained in the step (1) and the fat-soluble raw ingredients obtained in the step (2), homogenizing under 150bar pressure, and cooling to 4 ℃;

(4) adding a matched amount of compound vitamin and compound mineral substance, uniformly stirring, sterilizing at 88 ℃ for 35s, concentrating at 86 ℃, spray-drying, and drying by a fluidized bed to obtain base powder, wherein the air inlet temperature of the spray-drying is 200 ℃, the air exhaust temperature is 80 ℃, the temperatures of sections I, II and III of the fluidized bed in the drying process of the fluidized bed are 85 ℃, and the temperature of section IV of the fluidized bed is 35 ℃;

(5) and (5) dry-mixing the base powder obtained in the step (4) with functional ingredients containing lutein, taurine, L-carnitine tartrate, choline chloride and nucleotide to obtain the infant formula milk powder.

3. Results of the experiment

In order to verify the application effect of the 2' -FL, (GOS + FOS) and OPO nutritional components in the infant formula milk powder, the influence of the nutritional components on the intestinal health of infants is investigated by adopting an animal experiment. Newborn rat rats were selected as subjects to be studied and fed with 4 infant formulas (F1 formula containing no prebiotics; F2 formula containing (GOS: FOS) ═ 1: 1; F3 formula containing 2 '-FL (GOS + FOS ═ 9:1): OPO ═ 1.5:43: 40; F4 formula containing 2' -FL (GOS + FOS ═ 9:1): OPO ═ 7.5:43: 40). After feeding for 21 days, the pig is killed, and intestinal tissues and contents are taken for intestinal health related index detection.

Fig. 3 shows the relative abundance of bifidobacteria in the intestine of pups after feeding formula containing different prebiotics. From fig. 3, it can be seen that the relative abundance of the bifidobacteria in the F2, F3 and F4 groups is significantly higher than that in the F1 group (p < 0.05), which indicates that the formula milk powder added with prebiotics can significantly promote the colonization of the bifidobacteria in the intestinal tract. Wherein F3 and F4 are obviously higher than F2(p is less than 0.05), which indicates that the intervention of the four nutrient components has better effect than the intervention of two common prebiotics. And no significant difference (p is more than 0.05) exists between the four nutritional component intervention groups F3 and F4, which shows that the further improvement of the relative content of 2' -FL has no significant influence on the colonization of the Bifidobacterium.

The results of the study on proliferation, differentiation and barrier function of intestinal epithelial cells after feeding with different formula milk powder are shown in table 4, and it can be seen from the table that the expressions of Ki-67, 5-HT, MUC2 and lysozyme positive cells after the formula milk powder of F3 group and F4 group is dried are all significantly higher than those of F1 group and F2 group, but there is no significant difference between F3 group and F4 group. This shows that the intervention of the four nutritional components can promote the development of the intestinal epithelial cells, but the increase of the adding proportion of the 2' -FL cannot further produce positive synergism.

TABLE 4 Effect of different infant formulas on the development of intestinal epithelial cells

The content of SCFAs in the colon of the rat pup after dry prediction of the milk powder with different formulas is different: from table 5 it can be seen that the total SCFAs content was significantly higher for the F3 and F4 groups than for the remaining two groups, but the total butyrate content was higher for the F3 group than for the F4 group. The result shows that the formula F3 can remarkably promote the generation of SCFAs in the intestinal tract by intervening the formula milk powder.

TABLE 5 SCFAs content in colon after intervention with different infant formulas (μmol/g)

The relative content of sIgA in intestinal contents of newborn mice after feeding different formula milk powders is shown in FIG. 4. It can be seen from fig. 4 that the relative content of sIgA in F3 group and F4 group is significantly higher than that in F1 group and F2 group, and the difference is significant after the difference significance test (p < 0.05). While the mean value between groups was slightly higher for the F3 group than for the F4 group, although there was no significant difference between the F3 and F4 groups. This shows that the intervention of the formula milk powder in the F3 group is helpful to promote the intestinal immune function development of the newborn mice.

The results of the above experiments show that the infant formula powder of the F3 group, including 2' -FL (GOS + FOS ═ 9:1) and OPO ═ 1.5:43:40, can significantly promote the intestinal health of newborn mice.

Example B2: formula milk powder beneficial to intestinal health of middle-aged and elderly people

1. Raw materials

H1 formulation:

41.31% of full cream milk powder, 31.06% of skim milk powder, 1% of refined soybean oil, 10% of lactose, 0.045% of galacto-oligosaccharide (GOS), 0.043% of fructo-oligosaccharide (FOS), 0.2% of soybean lecithin, 15% of maltodextrin, 0.15% of compound vitamin, 0.038% of ferrous sulfate, 1% of calcium carbonate, 0.013% of zinc sulfate, 0.038% of citric acid and 0.1% of potassium hydroxide.

The compound vitamin comprises 0.85% of vitamin A acetate powder, 0.01% of vitamin D3 powder, 62.7% of L-ascorbic acid, 22.28% of L-sodium ascorbate and 14.16% of dl- α -tocopherol acetate powder.

Wherein the ratio of GOS to FOS is about 1: 1.

H2 formulation:

41% of full-cream milk powder, 31.05% of skim milk powder, 10% of lactose, 0.015% of 2' -FL, 0.387% of galacto-oligosaccharide (GOS), 0.043% of fructo-oligosaccharide (FOS), 1% of OPO structural fat mixed oil (containing 0.4% of OPO), 0.2% of soybean lecithin, 15% of maltodextrin, 0.15% of vitamin complex, 0.038% of ferrous sulfate, 1% of calcium carbonate, 0.013% of zinc sulfate, 0.038% of citric acid and 0.1% of potassium hydroxide.

Wherein, the OPO structure fat mixed oil is composed of sunflower seed oil, coconut oil, soybean oil and linseed oil, the proportion of the OPO structure fat mixed oil is 42%, 36%, 16% and 6%, wherein, the proportion of the 1, 3-dioleoyl-2-palmitic acid triglyceride in the mixed oil is 40%.

The compound vitamin comprises 0.85 percent of vitamin A acetate powder, 0.01 percent of vitamin D3 powder, 62.7 percent of L-ascorbic acid, 22.28 percent of L-sodium ascorbate and 14.16 percent of dl- α -tocopheryl acetate powder.

Wherein the ratio of 2' -FL, (GOS + FOS) and OPO is 1.5:43: 40.

H3 formulation:

40.94% of full cream milk powder, 31.05% of skim milk powder, 10.03% of lactose, 0.075% of 2' -FL, 0.387% of galacto-oligosaccharide (GOS), 0.043% of fructo-oligosaccharide (FOS), 1% of OPO structural fat mixed oil (containing 0.4% of OPO), 0.2% of soybean lecithin, 15% of maltodextrin, 0.15% of compound vitamin, 0.038% of ferrous sulfate, 1% of calcium carbonate, 0.013% of zinc sulfate, 0.038% of citric acid and 0.1% of potassium hydroxide.

Wherein, the OPO structure fat mixed oil is composed of sunflower seed oil, coconut oil, soybean oil and linseed oil, the proportion of the OPO structure fat mixed oil is 42%, 36%, 16% and 6%, wherein, the proportion of OPO in the mixed oil is 40%.

Wherein the ratio of 2' -FL, (GOS + FOS) and OPO is 7.5:43: 40.

2. Preparation method

(1) Putting water-soluble ingredients including whole milk powder, skimmed milk powder, lactose, maltodextrin, 2' -FL, fructo-oligosaccharide (FOS) and galacto-oligosaccharide (GOS) into purified water at 60 deg.C to obtain water-soluble raw ingredients;

(2) heating the OPO structure fat mixed oil to 60 ℃ to obtain a fat-soluble raw ingredient;

(3) mixing water soluble and liposoluble raw materials, homogenizing (pressure 150bar), and cooling to 4 deg.C;

(4) adding compound vitamins, ferrous sulfate, calcium carbonate, zinc sulfate and other food additives (citric acid and potassium hydroxide), stirring, sterilizing (88 deg.C for 35s), concentrating (86 deg.C), spray drying (air inlet temperature of 200 deg.C and air exhaust temperature of 80 deg.C), fluidized bed drying, and spraying soybean phospholipid (85 deg.C in sections I, II and III, and 35 deg.C in section IV).

3. Results of the experiment

In order to examine the influence of different nutritional components on the constitution of intestinal flora of the elderly, an in vitro experiment method is adopted, 10 healthy elderly feces samples are collected and mixed, then the feces samples are cultured, different nutritional components are applied during the culture process (H1 formula milk powder contains GOS: FOS ═ 1: 1; H2 formula milk powder contains 2 '-FL (GOS + FOS ═ 9:1): OPO ═ 1.5:43: 40; H3 formula milk powder contains 2' -FL (GOS + FOS ═ 9:1): OPO ═ 7.5:43:40), and the growth condition of bifidobacterium in the feces of the elderly is observed after 24 hours of culture. The experimental results are shown in fig. 5, and it can be seen from fig. 5 that the growth amounts of the bifidobacteria of the H2 and H3 groups are significantly higher than those of the H1 group (p < 0.05), and the growth amount of the H3 group is slightly higher than that of the H2 group, but there is no significant difference between the two groups (p > 0.05). This suggests that the nutritional composition containing 2' -FL (GOS + FOS ═ 9:1) and OPO ═ 1.5:43:40 helps to promote the proliferation of bifidobacteria in the gut of elderly people.

Example B3: formula milk powder beneficial to intestinal health of pregnant and lying-in women

1. Raw materials

Formulation of W1:

36.2% of whole milk, 30.08% of skim milk powder, 5.9% of concentrated whey protein powder, 5.8% of lactose, 0.04% of galacto-oligosaccharide (GOS), 0.036% of fructo-oligosaccharide (FOS), 0.36% of refined soybean oil, 16.69% of maltodextrin, 2% of white granulated sugar, 0.5% of soybean lecithin, 0.19% of choline chloride, 1.7% of docosahexaenoic acid, 0.25% of vitamin complex, 0.068% of ferrous sulfate, 0.027% of zinc sulfate, 0.013% of copper sulfate, 0.042% of citric acid monohydrate and 0.1% of potassium hydroxide.

Wherein the ratio of GOS to FOS is about 1: 1.

Formulation of W2:

36.18% of whole milk, 29.19% of skim milk powder, 5.9% of concentrated whey protein powder, 5.8% of lactose, 0.015% of 2' -FL, 0.387% of galacto-oligosaccharide (GOS), 0.043% of fructo-oligosaccharide (FOS), 1% of OPO structural fat mixed oil (containing 0.4% of OPO), 16.69% of maltodextrin, 2% of white granulated sugar, 0.5% of soybean lecithin, 0.19% of choline chloride, 1.7% of docosahexaenoic acid, 0.25% of vitamin complex, 0.068% of ferrous sulfate, 0.027% of zinc sulfate, 0.013% of copper sulfate, 0.042% of citric acid monohydrate and 0.1% of potassium hydroxide.

Wherein the ratio of 2' -FL, (GOS + FOS) and OPO is 1.5:43: 40.

Formulation of W3:

36.18 percent of whole milk, 29.06 percent of skim milk powder, 5.9 percent of concentrated whey protein powder, 5.8 percent of lactose, 0.075 percent of 2' -FL, 0.387 percent of galacto-oligosaccharide (GOS), 0.043 percent of fructo-oligosaccharide (FOS), 1 percent of OPO structural fat mixed oil (containing 0.4 percent of OPO), 16.69 percent of maltodextrin, 2 percent of white granulated sugar, 0.5 percent of soybean lecithin, 0.19 percent of choline chloride, 1.7 percent of docosahexaenoic acid, 0.25 percent of compound vitamin, 0.068 percent of ferrous sulfate, 0.027 percent of zinc sulfate, 0.013 percent of copper sulfate, 0.042 percent of citric acid monohydrate and 0.1 percent of potassium hydroxide.

Wherein the ratio of 2' -FL, (GOS + FOS) and OPO is 7.5:43: 40.

2. Preparation method

(1) Putting water-soluble ingredients including whole milk, skimmed milk powder, concentrated whey protein powder, lactose, 2' -FL, galacto-oligosaccharide (GOS), fructo-oligosaccharide (FOS), maltodextrin and white sugar into purified water of 40-65 deg.C to obtain water-soluble raw ingredients;

(2) heating the OPO structure fat mixed oil to 40-65 ℃ to obtain a fat-soluble raw ingredient;

(3) mixing water-soluble and fat-soluble raw materials, homogenizing (pressure 100-;

(4) adding compound vitamins, ferrous sulfate, zinc sulfate, copper sulfate and other food additives (citric acid monohydrate and potassium hydroxide), stirring uniformly, sterilizing (temperature is 75-95 ℃ and time is 20-90s), concentrating (temperature is 70-90 ℃), spray drying (air inlet temperature is 180 ℃ and 215 ℃ and air exhaust temperature is 70-90 ℃), drying by a fluidized bed, and spraying soybean lecithin (temperature is 15-95 ℃ in sections I, II and III and temperature is 15-40 ℃ in section IV of the fluidized bed);

(5) and (3) feeding the dried base powder into a dry mixing tank through a powder conveying system, and dry mixing the dried base powder with functional ingredients to be dry mixed, namely choline chloride and docosahexaenoic acid to obtain the pregnant and lying-in woman formula milk powder.

3. Results of the experiment

In order to examine the influence of different nutritional components on the constitution of intestinal flora of pregnant women, an in vitro experiment method is adopted, 10 feces samples of pregnant women in the middle period of pregnancy are collected and mixed for culture, the different nutritional components are interfered during the culture process (W1 formula milk powder contains GOS: FOS ═ 1: 1; W2 formula milk powder contains 2 '-FL (GOS + FOS ═ 9:1), OPO ═ 1.5:43: 40; W3 formula milk powder contains 2' -FL (GOS + FOS ═ 9:1), OPO ═ 7.5:43:40), and the growth condition of the Bifidobacterium in the feces of the pregnant women is observed after 24 hours of culture. The experimental results are shown in fig. 6, and it can be seen from the graph that the increase ratio of the relative abundance of the bifidobacteria of the W2 and W3 groups is significantly higher than that of the W1 group (p < 0.05), and the increase of the W3 group is slightly higher than that of the W2 group, but there is no significant difference between the two groups (p > 0.05). This demonstrates that a nutritional composition containing 2' -FL (GOS + FOS ═ 9:1) and OPO ═ 1.5:43:40 helps to promote the proliferation of bifidobacteria in the gut of pregnant women in mid-term pregnancy.

The foregoing is only an embodiment of the present invention, and it should be noted that, for those skilled in the art, modifications can be made to the chemical substituents of the ligand without departing from the inventive concept, so as to achieve the purpose of adjusting and controlling the color and efficiency of the complex, but these are all within the scope of the present invention.

Claims

1. A nutritional component comprising Human Milk Oligosaccharides (HMOs), Galactooligosaccharides (GOS), and Fructooligosaccharides (FOS), wherein the weight ratio of GOS to FOS is about 9: 1.

2. The nutritional component of claim 1, wherein the weight ratio of HMOs to GOS and FOS of about 9:1 is from about 1:1 to about 1:200, preferably from about 1:2 to about 1:100, more preferably from about 1:2 to about 1:30, especially preferably about 1:5, 1:10, 1:15, 1:20, 1:25, 1:30, 1:40, 1:60 or 1: 90.

3. The nutritional composition of claim 1 or 2 further comprising 1, 3-dioleoyl-2-palmitoyl-triglyceride (OPO); preferably, the weight ratio of HMO to OPO is from about 1:1 to about 1:200, preferably from about 1:2 to about 1:200, more preferably from about 1:2 to about 1:80, especially preferably about 1:10, 1:20, 1:40, 1:60 or 1: 80.

4. The nutritional component according to any one of claims 1-3 wherein the HMO is selected from the group consisting of fucosyl-enriched human milk oligosaccharides such as 2 '-FL, 3-FL, LNFP I, LNFP II, LNFP III, LNFP V, LNFP VI, LNDFH I, LNDFH II, F-LNHI, F-LNH II, DF-LNH I, DF-LNH II, DF-LNnH, DF-para-LNH, DF-para-LNnH, TF-LNH and the like, preferably 2' -FL.

5. The nutritional component of any one of claims 1 to 4 comprising 2' -FL, GOS, FOS and OPO in a weight ratio of about (0.5-10): 35-40: (3.5-4.5): 40, preferably (1-10): 35-40: (3.5-4.5): 40.

6. Food or health product comprising the nutritional component according to any one of claims 1 to 5.

7. The food or health product of claim 6, wherein the food or health product is a milk and dairy product, a fermented flavor food, a beverage, chocolate, candy, baked goods, a juice food; preferably, the food or health product is meat, fish, poultry and wild, gravy, pickled, frozen, dried and cooked fruits and vegetables, jelly, jam, preserves, eggs, milk and dairy products, edible oils and fats.

8. The food or health product according to claim 6 or 7, wherein the food or health product is an infant, a maternal and elderly formula, raw or processed cheese, a milk drink, a solid dairy product, a solid drink, ice cream.

9. Use of the nutritional component according to any one of claims 1 to 5 for the preparation of a food or health product, wherein the food or health product is a milk and dairy product, a fermented flavoured food, a beverage, chocolate, a confectionery, a bakery product, a fruit and vegetable juice food; preferably, the food or health product is meat, fish, poultry and wild, gravy, pickled, frozen, dried and cooked fruits and vegetables, jelly, jam, preserves, eggs, milk and dairy products, edible oils and fats.

10. Use according to claim 9, wherein the food or health product is an infant, a maternal and a senior formula, raw or processed cheese, a milk drink, a solid dairy product, a solid drink, ice cream.

11. A process for the preparation of an infant formula containing the nutritional components according to any one of claims 1-5, comprising the steps of:

preferably, the homogenization pressure is about 100-200 bar;

12. A method for preparing a senior formula comprising the nutritional composition of any one of claims 1-5 comprising the steps of:

(2) heating oil to about 40-65 deg.C to obtain liposoluble raw materials;

preferably, the grease is OPO structure grease mixed oil;

preferably, the homogenization pressure is about 100-200 bar;

13. A method for preparing a maternal formula containing the nutritional components of any one of claims 1 to 5, comprising the steps of:

(2) heating oil to about 40-65 deg.C to obtain liposoluble raw materials;

preferably, the grease is OPO structure grease mixed oil;

preferably, the homogenization pressure is about 100-200 bar;